Sorafenib (Nexavar, BAY43-9006)
13266
Phase 3 small_molecule completed
Quick answer
Sorafenib (Nexavar, BAY43-9006) for Carcinoma is a Phase 3 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer HealthCare AG
- Indication
- Carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed